Progress on ARIAD's Iclusig - Analyst Blog

By
A A A

ARIAD Pharmaceuticals, Inc. ( ARIA ) recently completed 50% enrollment in the randomized phase III EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) study being conducted on Iclusig (ponatinib) in newly diagnosed chronic myeloid leukemia (CML) patients. EPIC will evaluate treatment-naive CML patients.

The randomized (1: 1 ), two-arm, multicenter EPIC study will compare the efficacy of Iclusig with that of  Novartis' ( NVS ) Gleevec (imatinib) in newly diagnosed in adult CML patients. Full enrolment of 500 patients is likely to complete by the end of 2013.

The primary endpoint of the study is major molecular response (MMR) of patients at 1 year of treatment. Main secondary endpoints include MMR at five years and molecular response (MR) at three months of treatment. 

Interim analysis of the study is due in the third quarter of 2014.

Iclusig, a tyrosine kinase inhibitor (TKI), launched in the U.S. in Jan 2013, is currently marketed by Ariad for treating adults suffering from CML, and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), who are resistant or intolerant to TKI therapy. Ariad recorded Iclusig sales of $13.9 million in the second quarter of 2013.

In Jul 2013, Ariad gained EU approval for Iclusig in two indications. The first indication is the treatment of chronic phase, accelerated phase or blast phase CML in adults who do not respond to or cannot tolerate Sprycel or Tasigna. It is also approved for patients in whom Gleevec is not appropriate as a subsequent treatment. The second indication covers the treatment of Ph+ ALL in adults unresponsive to Sprycel. It also includes patients for whom Gleevec is not clinically appropriate. Iclusig is also approved for patients who have the T315I mutation.

Ariad currently carries a Zacks Rank # 3 (Hold). Other stocks that look attractive include Biogen Idec Inc . ( BIIB ) and Affymetrix Inc. ( AFFX ) . Both carry a Zacks Rank #1 (Strong Buy).



AFFYMETRIX INC (AFFX): Free Stock Analysis Report

ARIAD PHARMA (ARIA): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AFFX , ARIA , BIIB , MR , NVS

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

48,099,947
  • $16.09 ▲ 0.50%
40,277,806
  • $102.50 ▲ 0.24%
40,236,499
  • $19.57 ▲ 2.35%
31,092,510
  • $49.75 ▲ 0.65%
30,795,218
  • $34.92 ▲ 0.78%
29,910,855
  • $3.63 ▲ 0.83%
24,019,154
  • $13.06 ▼ 0.38%
23,753,906
  • $74.82 ▲ 1.31%
As of 8/29/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com